Event Details
Not specified (described as ongoing)
Description
ODYSSEY OUTCOMES trial: An ongoing trial to prospectively evaluate the cardiovascular benefits of Praluent in approximately 18,000 patients.
Participants (1)
| Name | Type | Mentions | |
|---|---|---|---|
| 18,000 patients | person | 0 | View Entity |
Source Documents (1)
HOUSE_OVERSIGHT_026366.jpg
Corporate Communication / Product Information Sheet
• 2.38 MB
This document is a corporate communication and product information sheet for the prescription drug Praluent (alirocumab), manufactured by Sanofi. It details the ODYSSEY clinical trial program, provides important safety information for patients, and includes a legal disclaimer. The document is marked with the identifier 'HOUSE_OVERSIGHT_026366' but contains no information whatsoever related to Jeffrey Epstein, his associates, finances, or travel.
Event Metadata
Type
Unknown
Location
Not specified
Significance Score
5/10
Participants
1
Source Documents
1
Extracted
2025-11-19 04:17
Additional Data
Source
HOUSE_OVERSIGHT_026366.jpg
Date String
Not specified (described as ongoing)
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein event